anti-CYLD (CYLD) Antikörper

Human Cylindromatosis (Turban Tumor Syndrome) (CYLD) Interaktionspartner

1. We detected three CYLD splice site mutations, designated c.2108+1G>A, c.2242-2A>G and c.2109-2A>C. These mutations were associated with distinct phenotypes.

2. CYLD in the vasculature may be a novel therapeutic target, especially in the early preventive intervention against the initiation of age-related atherogenesis.

3. Downregulation of CYLD promotes invasion with mesenchymal transition via ALK5 stabilization in oral squamous cell carcinoma cells.

4. CYLD suppression enhanced the production of pro-inflammatory cytokines in synoviocytes from rheumatoid arthritis patients.

5. Our study revealed high incidence and sequential CYLD mutations in both basal cell adenoma and adenocarcinoma supporting a single neoplastic continuum for their evolution

6. Study reveals alterations of the CYLD gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Also, a recurrent missense mutation found in the kinase domain of the ALPK1 gene in spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of CYLD and can activate the NF-kappaB pathway in reporter assays.

7. miR-301b plays an oncogenic role in triple negative breast cancer (TNBC) possibly by downregulating CYLD and subsequently activating NF-kappaB p65, and this may provide a novel therapeutic approach for TNBC.

8. Study revealed that miR-182 expression was significantly upregulated in human gastrointestinal stromal tumors (GISTs) compared with adjacent normal tissues. Overexpression of miR-182 enhanced GIST-T1 cell growth, with increased proliferation and decreased apoptosis. In addition, cylindromatosis (CYLD) was identified as a direct target of miR-182.

9. A substantial number of CLL patient samples express sCYLD.

10. No genotype-phenotype correlation was found in tumor disorders of the skin appendages associated with mutations in the CYLD gene.

11. Catalytic domain mutation in CYLD gene is associated with osteosarcoma.

12. Studied the role of maternally expressed 3 (lncRNA-MEG3) as an antitumor lncRNA for malignant melanoma by regulating miR-499-5p/CYLD axis.

13. CYLD inhibits post-transcriptional regulation of RIG-I and MDA5 expression following TLR3 activation in MCs. CYLD may be involved in the pathogenesis of CKD

14. miR-197-3p-induced downregulation of CYLD promotes cell proliferation and inhibits cell apoptosis in lung adenocarcinoma cell lines.

15. Knockdown of CYLD expression reversed the cell proliferation promotion by miR1288in in glioblastoma.

16. TNF phase III signalling displays ongoing TNFR1/NF-kappa B activation in monocytic cells. High- and low-sensitive genes are induced including differentially regulated A20. A20 strictly controls this signalling in an IKK- and partially RIP-dependent manner. The A20-mediated control mechanisms are supported by ABIN1 and CYLD.

17. Low expression of CYLD is associated with glioma.

18. theses data show that CYLD regulates the magnitude of ubiquitination of several major effectors of the EGFR pathway by assisting the recruitment of the ubiquitin ligase Cbl-b to the activated EGFR complex.

19. Through deceasing the expression of Cylindromatosis (CYLD), a K63-specific DUB and endogenous blocker of NF-kappaB signaling, miR-130b can in return sustain the persistent activation of NF-kappaB, which may promote the malignant progression of transitional cell carcinoma of bladder.

20. While previous reports have described CYLD as a regulator of DVL proteins; this data suggests the presence of a more complicated reciprocal regulatory mechanism in CML cell lines.

Mouse (Murine) Cylindromatosis (Turban Tumor Syndrome) (CYLD) Interaktionspartner

1. CYLD in the vasculature may be a novel therapeutic target, especially in the early preventive intervention against the initiation of age-related atherogenesis.

2. IL-33 mediated immunoregulation in pulmonary adenocarcinoma by improving DC-induced T cell proliferation by upregulating CYLD expression

3. our findings demonstrate that CYLD mitigates Nonalcoholic steatohepatitis severity and identify the CYLD-TAK1 axis as a promising therapeutic target for management of the disease.

4. Loss of CYLD catalytic activity causes impaired DNA damage-induced p53 stabilization and activation in epithelial cells and sensitizes mice to chemical carcinogen-induced intestinal and skin tumorigenesis.

5. The present results support the involvement of CYLD in the regulation of NF-kappaB inflammatory signaling induced by elevated glucose, implicating CYLD as a potential therapeutic target of diabetic nephropathy .

6. the role of CYLD in development, tissue homeostasis, and tumorigenesis

7. Findings provide physiological insight into the ciliary role of the CYLD/HDAC6 axis and suggest a functional interplay between these two proteins in ciliary homeostasis.

8. Thrombin-mediated MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage.

9. SPATA2 has been described as a previously unrecognized factor in the linear ubiquitin chain assembly complex-dependent signaling pathways that serves as an adaptor between HOIP and CYLD, thereby enabling recruitment of CYLD to signaling complexes.

10. TLR4 activates CASPASE-8 to cleave and remove the deubiquitinase cylindromatosis (CYLD) in a TRIF- and RIPK1-dependent manner to disable necroptosis in macrophages.

11. CYLD contributes to the transdifferentiation of adventitial fibroblasts via deubiquitinating Nox4 and may play a role in vascular remodeling.

12. this study shows that by polarization of the T cell cytokine response, CYLD can favor the development of allergic airway disease

13. Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis

14. Deubiquitinase CYLD negatively regulates MyD88-mediated signaling by directly interacting with MyD88 and deubiquitinating nontypeable Haemophilus influenzae (NTHi)-induced K63-linked polyubiquitination of MyD88 at lysine 231.

15. CYLD interrupts the ERK- and p38-/AP-1 and c-Myc pathways to suppress Nrf2-operated antioxidative capacity, thereby enhancing oxidative stress in the heart.

16. Our data demonstrate that inefficient negative selection in the thymus of CYLD(ex7/8) mice result from a defect in mTEC maturation.

17. The deubiquitinating enzyme CYLD controls apical docking of basal bodies in ciliated epithelial cells.

18. Data show that the in utero death of NF-NF-kappaB essential modulator (NEMO) and cylindromatosis protein double mutant mice is mediated by TNF receptor 1 (TNFR1) signaling and can be rescued by TNFR1 deficiency.

19. CYLD is a central regulator of apoptotic cell death in murine hepatocytes by controlling NF-kappaB dependent anti-apoptotic signaling.

20. In contrast to full-length CYLD, the immune function of short splice variant CYLD (sCYLD) is insufficiently described. To explore sCYLD's function in infection, investigated whether dendritic cell-specific sCYLD regulates the pathogenesis of listeriosis.

Zebrafish Cylindromatosis (Turban Tumor Syndrome) (CYLD) Interaktionspartner

1. The crystal structures representing the catalytic states of zebrafish CYLD for Met1- and Lys63-linked Ub chains and two distinct precatalytic states for Met1-linked chains are presented.